Reduction−Alkylation Strategies for the Modification of Specific Monoclonal Antibody Disulfides
Michael Sun(Seagen (United States)), Stephen C. Alley(Seagen (United States)), Michael Torgov(Seagen (United States)), Charles G. Cerveny(Seagen (United States)), Kevin S. Beam(Seagen (United States)), Richard S. Blackmore(Seagen (United States)), Peter D. Senter(Seagen (United States)), Felicia G. M. Handley(Seagen (United States)), Nathan C. Ihle(Seagen (United States)), Kevin J. Hamblett(Seagen (United States))
Cited by 365
Related Papers
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
|Clinical Cancer Research|2004|1.2k
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
|Nature Biotechnology|2003|1.2k
Arming antibodies: prospects and challenges for immunoconjugates
|Nature Biotechnology|2005|1k
cAC10-vcMMAE, an anti-CD30–monomethyl auristatin E conjugate with potent and selective antitumor activity
|Blood|2003|918
Antibody–drug conjugates come of age in oncology
|Nature Reviews Drug Discovery|2023|772